Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures
OSAKA, Japan, May 9 (Bernama-BUSINESS WIRE) — Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into agreements to divest its Xiidra® (lifitegrast ophthalmic solution) 5% product (“Xiidra®”) to Novartis and its TachoSil®Fibrin Sealant Patch (“TachoSil®”) to Ethicon as part of its strategy to focus on business areas core…

